Reuters
01 Sept 2026, 06:15 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
2 claims · each scored for market impact
GSK's mRNA-based seasonal influenza vaccine candidate generated stronger immune responses than current standard- and high-dose shots in mid-stage data. — Superior efficacy data compared to established standards significantly increases the probability of commercial success and market share capture.
+0.60GSK is advancing its mRNA influenza vaccine candidate into a late-stage trial. — Progression to late-stage trials reduces clinical risk and moves the product closer to potential regulatory approval and revenue generation.
+0.30Which stocks this story touches
The company is advancing an mRNA vaccine candidate into late-stage trials after positive mid-stage data showing superior immune responses.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
3h ago
